Expression of Ki-67 and Bcl-2 biomarkers in normal breast tissue from women of reproductive age treated with raloxifene

Archives of Gynecology and Obstetrics

Volumn 285, Issue 1, 2012, Pages 223-227

  Lima, Marina Ayres Vilarinho Corrêa ^a   Da Silva, Benedito Borges ^a  

^a Hosp Getulio Vargas   (Brazil)

Author keywords

Apoptosis; Bcl 2; Ki 67; Normal breast; Proliferation; Raloxifene

Indexed keywords

KI 67 ANTIGEN; PLACEBO; PROTEIN BCL 2; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TUMOR MARKER;

ADULT; AGE; ANTIGEN EXPRESSION; ARTICLE; BIOPSY TECHNIQUE; BREAST BIOPSY; BREAST FIBROADENOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXCISIONAL BIOPSY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MENSTRUAL CYCLE; PREMENOPAUSE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REPRODUCTION; TREATMENT DURATION; ADOLESCENT; BIOPSY; BIOSYNTHESIS; BREAST; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FIBROADENOMA; METABOLISM; PATHOLOGY;

ADOLESCENT; ADULT; BIOPSY; BREAST; BREAST NEOPLASMS; FEMALE; FIBROADENOMA; HUMANS; KI-67 ANTIGEN; PROTO-ONCOGENE PROTEINS C-BCL-2; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84860827625     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-011-1932-8     Document Type: Article

References (28)

1. Instituto nacional do cancer (INCA) (2008) Estimativa da incidência e mortalidade por câncer no Brasil. Disponível. http://www.inca.gov.br/. (Acesso em setembro de 2009)
2. OK Lewis JS, Jordan VC (2005) Selective estrogen receptor modulators (SERMS): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 591(1-2):247-263
3. OK Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robodoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N (2005) Tamoxifen for prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project p-1 study. J Natl Cancer Inst 97(22):1636-1637
4. Singh MN, Stringfellow HF, Paraskevaidis E, Martin-hirsch PL, Martin FL (2007) Tamoxifen: important considerations of a multi-functional compound with organ-specific properties. Cancer Treat Rev 33(2):91-100
5. da Silva BB, Lopes IM, Gebrim LH (2006) Effects of raloxifene on normal breast tissue from premenopausal women. Breast Cancer Res Treat 95(2):99-103
6. OK Muchmore DB (2000) Raloxifene: a selective estrogen receptor modulator (SERM) with multiple target system effects. Oncologist 5:388-392
7. OK Olevsky OM, Martino S (2008) Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women. Menopause 15(4):790-796
8. OK Gerdes J, Lelle RJ, Pickartz H, Heidenreich W, Schwarting R, Kurtsiefer L, Stauch G, Stein H (1986) Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. J Clin Pathol 39(9):977-980
9. OK Kariya S, Ogawa Y, Nishioka A, Moriki T, Ohnishi T, Ito S, Murata Y, Yoshida S (2005) Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients. Radiat Med 23(3): 189-194
10. Kushlinskii NE, Orinovskii MB, Gurevich LE, Kazantseva IA, Talaeva ShZh, Shirokii VP, Ermilova VD, Dvrova EK, Ozherelev AS (2004) Expression of biomolecular markers (Ki-67, PCNA, Bcl-2, BAX, Bcl-x, VEGF) in breast tumors. Bull Exp Biol Med 137(2):182-185
11. Estevão RAF, Baracat EC, Logullo AF, Oshima CTF, Nazario ACP (2007) Efficacy of estriol in inhibiting epithelial proliferation in mammary fibroadenoma: randomized clinical trial. São Paulo Med J 125(6):343-350
12. Cauley J, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, KW NG, Stepan JJ, Powless TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4 year results from MORE Trial. Breast Cancer Res Treat 67(2):191
13. OK Wintzer HO, Zipfel I, Schulte-Monting J, Hellerich U, von Kleist S (1991) Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67(2):421-428
14. Leers MPG, Theunissen PHMH, Ramaekers FCS, Schutte B (1997) Multi-parameter flow cytometric analysis with detection of Ki-67-Ag in paraffin embedded mammary carcinomas. Cytometry 27(3):283-289
15. Rudolph P, Peters J, Lorenz D, Schimidt D, Parwaresch R (1998) Correlation between mitotic and Ki-67 labeling in paraffinembedded carcinoma specimens. Human Pathol 29(1):1216-1222
16. Dardes RDM, Horiguchi J, Jordan VC (2000) A pilot study of the effects of short-term tamoxifen therapy on Ki-67 labeling index in women with primary breast cancer. Int J Oncol 16(1):25-30
17. OK Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 281(23): 2189-2197
18. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR, CORE Investigators (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst; 96(23):1751-1761
19. Nazario ACP, de Lima RG, Simões MJ, Novo NF (1995) Cell Kinetics of human mammary lobule during the proliferative and secretory phase of the menstrual cycle. Bull Assoc Anat 79(244): 23-27
20. Facina G, de Lima GR, Simões MJ, Novo NF, Gebrim LH (1997) Estrogenic activity of tamoxifen on normal mammary parenchyma in the luteal phase of the menstrual cycle. Int J Gynecol Obstet 569(1):19-24
21. Bernardes JR Jr, Nonogaki S, Seixas MT, De Rodrigues Lima G, Baracat EC, Gebrim LH (1999) Effect of a half-dose tamoxifen on proliferative activity in normal breast tissue. Int J Gynecol Obstet 67(1):33-38
22. OK Dowsett M, Archer C, Assersohn L, Gregory RK, Ellis PA, Salter J, Chang J, Mainwaring P, Boeddinghaus I, Johnston SR, Powles TJ, Smith IE (1999) Clinical studies of apoptosis and proliferation in breast cancer. Endocr Relat Cancer 6:25-28
23. Johnston SRD, Maclennan KA, Sacks NPM, Salter J, Smith IE, Dowsett M (1994) Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer 30A(11):1663-1669
24. Ferguson DJP, Anderson TJ (1981) Ultrastructural observations on cell death by apoptosis in the resting human breast. Virchows Arch 393:193-203
25. OK Hockenberry DM, Zutter M, Hickey W, Nahm M, Kosmeyer SJ (1991) Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88:6961-6965
26. OK Cameron DA, Keen JC, Dixon JM, Bellamy C, Hanby A, Anderson TJ, Miller WR (2000) Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes. Eur J Cancer 36:845-851
27. OK Lopes-Costa PV, Dos Santos AR, Dos Santos LG, da Silva BB (2010) Evaluation of Ki-67 and Bcl-2 antigen expression in breast carcinomas of women treated with raloxifene. Cell Prolif 43: 124-129
28. Rosal MA, da Silva BB (2011) Evaluation of estrogen and progesterone receptors in non-neoplastic breast tissue of women of reproductive age exposed to tamoxifen and raloxifene: a randomized, double-blind study. Breast Cancer Res Treat 125: 797-801